2012 focused update of the ESC Guidelines for the management of atrial fibrillation

An update of the 2010 ESC Guidelines for the management of atrial fibrillation
Developed with the special contribution of the European Heart Rhythm Association

Authors/Task Force Members: A. John Camm (Chairperson) (UK)*, Gregory Y.H. Lip (UK), Raffaele De Caterina (Italy), Irene Savelieva (UK), Dan Atar (Norway), Stefan H. Hohnloser (Germany), Gerhard Hindricks (Germany), Paulus Kirchhof (UK)

ESC Committee for Practice Guidelines (CPG): Jeroen J. Bax (CPG Chairperson) (The Netherlands), Helmut Baumgartner (Germany), Claudio Ceconi (Italy), Veronica Dean (France), Christi Deaton (UK), Robert Fagard (Belgium), Christian Funck-Brentano (France), David Hasdai (Israel), Arno Hoes (The Netherlands), Paulus Kirchhof (Germany/UK), Juhani Knuuti (Finland), Philippe Kolh (Belgium), Theresa McDonagh (UK), Cyril Moulin (France), Bogdan A. Popescu (Romania), Željko Reiner (Croatia), Udo Sechtem (Germany), Per Anton Sirnes (Norway), Michal Tendera (Poland), Adam Torbicki (Poland), Alec Vahanian (France), Stephan Windecker (Switzerland)

Document Reviewers: Panos Vardas (Review Coordinator) (Greece), Nawwar Al-Attar (France), Ottavio Alfieri† (Italy), Annalisa Angelini (Italy), Carina Blömmstrom-Lundqvist (Sweden), Paolo Colonna (Italy), Johan De Sutter (Belgium), Sabine Ernst (UK), Andreas Goette (Germany), Bulent Gorenek (Turkey), Robert Hatala (Slovak Republic), Hein Heidbüchel (Belgium), Magnus Heldal (Norway), Steen Dalby Kristensen (Denmark), Philippe Kolh† (Belgium), Jean-Yves Le Heuzey (France), Hercules Mavrakis (Greece), Lluis Mont (Spain), Pasquale Perrone Filardi (Italy), Piotr Ponikowski (Poland), Bernard Prendergast (UK), Frans H. Rutten (The Netherlands), Ulrich Schotten (The Netherlands), Isabelle C. Van Gelder (The Netherlands), Freerk W.A. Verheugt (The Netherlands)

The disclosure forms of the authors and reviewers are available on the ESC website www.escardio.org/guidelines

* Corresponding authors: A. John Camm, Division of Clinical Sciences, St. George’s University of London, Cranmer Terrace, London SW17 0RE, United Kingdom.
Tel: +44 20 8725 3414. Fax: +44 20 8725 3416, Email: jcamm@sgul.ac.uk
† Representing the European Association for Cardio-Thoracic Surgery (EACTS).
Other ESC entities having participated in the development of this document:
• Associations: European Association of Echocardiography (EAE), European Association for Cardiovascular Prevention and Rehabilitation (EAPCR), Heart Failure Association (HFA).
• Councils: Council for Cardiology Practice, Council on Primary Cardiovascular Care.
• Working Groups: Acute Cardiac Care, Cardiovascular Surgery, Development, Anatomy and Pathology, Nuclear Cardiology and Cardiac Computed Tomography, Pharmacology and Drug Therapy, Thrombosis, Valvular Heart Disease.

The content of these European Society of Cardiology (ESC) Guidelines has been published for personal and educational use only. No commercial use is authorized. No part of the ESC Guidelines may be translated or reproduced in any form without written permission from the ESC. Permission can be obtained upon submission of a written request to Oxford University Press, the publisher of the European Heart Journal and the party authorized to handle such permissions on behalf of the ESC.

Disclaimer. The ESC Guidelines represent the views of the ESC and were arrived at after careful consideration of the available evidence at the time they were written. Health professionals are encouraged to take them fully into account when exercising their clinical judgement. The Guidelines do not, however, override the individual responsibility of health professionals to make appropriate decisions in the circumstances of the individual patients, in consultation with that patient and, where appropriate and necessary, the patient’s guardian or carer. It is also the health professional’s responsibility to verify the rules and regulations applicable to drugs and devices at the time of prescription.

© The European Society of Cardiology 2012. All rights reserved. For permissions please email: journals.permissions@oup.com
Keywords
Atrial fibrillation • European Society of Cardiology • Guidelines • Anticoagulation • Novel oral anticoagulants • Left atrial appendage occlusion • Rate control • Cardioversion • Rhythm control • Antiarrhythmic drugs • Upstream therapy • Pulmonary vein isolation • Left atrial ablation • Focused update

Table of Contents
Abbreviations and acronyms 2720
1. Preamble 2721
2. Introduction 2722
3. Stroke and bleeding risk assessment 2723
4. Novel oral anticoagulants 2725
  4.1. Dabigatran etexilate 2725
  4.2. Rivaroxaban 2725
  4.3. Apixaban 2726
  4.4. Practical considerations 2726
5. Left atrial appendage closure 2731
  5.1. Rationale and techniques for left atrial appendage closure 2731
  5.2. Results of left atrial appendage closure 2732
6. Cardioversion with pharmacological agents 2732
  6.1. Clinical evidence for vernakalan 2733
  6.2. Safety of vernakalan 2733
7. Oral antiarrhythmic drug therapy 2735
  7.1. Upstream therapy 2735
  7.2. Principles of antiarrhythmic drug therapy 2735
  7.3. Update on dronedarone 2737
8. Catheter ablation of atrial fibrillation 2739
  8.1. New evidence for catheter ablation 2739
  8.2. Catheter ablation in patients with heart failure 2740
  8.3. Antiarrhythmic therapy peri-afiblation 2740
  8.4. Safety first 2741
  8.5. New considerations for AF catheter ablation 2741
9. Concluding remarks 2741
References 2742

Abbreviations and acronyms
ACCF American College of Cardiology Foundation
ACCP American College of Chest Physicians
ACS acute coronary syndrome
ACT Atrial arrhythmia Conversion Trial
ADONIS American–Australian–African trial with DronedarOne In atrial fibrillation or flutter for the maintenance of Sinus rhythm
AF atrial fibrillation
AHA American Heart Association
ANDROMEDA ANtiarrhythmic trial with DROnedarone in Moderate-to-severe congestive heart failure Evaluating morbidity DecreaseA
APHRS Asia Pacific Heart Rhythm Society
aPTT activated partial thromboplastin time

ARB angiotensin-receptor blocker
ARISTOTLE Apixaban for Reduction In STroke and Other ThromboemboLic Events in atrial fibrillation
ATHENA A placebo-controlled, double-blind, parallel arm Trial to assess the efficacy of dronedarone 400 mg b.i.d. for the prevention of cardiovascular Hospitalization or death from any cause in patiENts with Atrial fibrillation/atrial flutter
ATRIA AnTicoagulation and Risk factors In Atrial fibrillation
AVERROES Apixaban VERSus acetylsalicylic acid (ASA) to Reduce the Rate Of Embolic Stroke in atrial fibrillation patients who have failed or are unsuitable for vitamin K antagonist treatment
AVRO A prospective, randomized, double-blind, Active-controlled, superiority study of Vernakalan vs. amiodarone in Recent Onset atrial fibrillation
b.i.d bis in die (twice daily)
b.p.m. beats per minute
CABANA Catheter ABlation vs. ANtiarrhythmic drug therapy for Atrial fibrillation
coronary artery bypass graft
CAP Continued Access to Protect AF
CHADS2 Congestive heart failure or left ventricular dysfunction Hypertension, Age ≥75 (doubled), Diabetes, Stroke (doubled)-Vascular disease, Age 65–74, Sex category (female)
CI confidence interval
CRAFT Controlled Randomized Atrial Fibrillation Trial
creatinine clearance
CrCl
DAFNE Dronedarone Atrial Fibrillation study after Electrical cardioversion
DIONYSOS Randomized Double blind trial to evaluate efficacy and safety of drONedarone (400 mg b.i.d.) vs. amiiodaroNe (600 mg q.d. for 28 daYS, then 200 mg qd thereafter) for at least 6 months for the maintenance of Sinus rhythm in patients with atrial fibrillation
EAST Early treatment of Atrial fibrillation for Stroke prevention Trial
EHRA European Heart Rhythm Association
electrocardiogram
ECG
EMA European Medicines Agency
ERATO Efficacy and safety of drOnedArone for The cOntrol of ventricular rate during atrial fibrillation
1. Preamble

Guidelines summarize and evaluate all currently available evidence on a particular issue with the aim of assisting physicians in selecting the best management strategy for an individual patient suffering from a given condition, taking into account the impact on outcome, as well as the risk–benefit ratio of particular diagnostic or therapeutic means. Guidelines are no substitutes for textbooks. The legal implications of medical guidelines have been discussed previously.

A large number of guidelines have been issued in recent years by the European Society of Cardiology (ESC) as well as by other societies and organizations. Because of the impact on clinical practice, quality criteria for development of guidelines have been established in order to make all decisions transparent to the user. The recommendations for formulating and issuing ESC Guidelines can be found on the ESC website (http://www.escardio.org/guidelines-surveys/esc-guidelines/about/Pages/rules-writing.aspx).

In brief, experts in the field are selected and undertake a comprehensive review of the published evidence for management and/or prevention of a given condition. A critical evaluation of diagnostic and therapeutic procedures is performed, including assessment of the risk–benefit ratio. Estimates of expected health outcomes for larger societies are included, where data exist. The level of evidence and the strength of recommendation of particular treatment options are weighed and graded according to pre-defined scales, as outlined in Tables 1 and 2.

The experts of the writing panels have provided disclosure statements of all relationships they may have that might be perceived as real or potential sources of conflicts of interest. These disclosure forms are kept on file at the European Heart House, headquarters of the ESC. Any changes in conflict of interest that arise during the writing period must be notified to the ESC. The Task Force report received its entire financial support from the ESC and was developed without any involvement of the pharmaceutical, device, or surgical industries.

The ESC Committee for Practice Guidelines (CPG) supervises and coordinates the preparation of new guidelines produced by Task Forces, expert groups, or consensus panels. The Committee is also responsible for the endorsement process of these guidelines or statements. Once the document has been finalized and approved by all the experts involved in the Task Force, it is submitted to outside specialists for review. The document is revised, finally approved by the CPG, and subsequently published.

After publication, dissemination of the message is of paramount importance. Pocket-sized versions and personal digital assistant (PDA) downloadable versions are useful at the point of care. Some surveys have shown that the intended users are sometimes unaware of the existence of guidelines, or simply do not translate them into practice. Thus, implementation programmes for new guidelines form an important component of knowledge dissemination. Meetings are organized by the ESC and directed towards its member National Societies and key opinion leaders in Europe. Implementation meetings can also be undertaken at national levels, once the guidelines have been endorsed by the ESC member societies and translated into the national language. Implementation programmes are needed because it has been shown that
the outcome of disease may be favourably influenced by the thorough application of clinical recommendations.

Thus, the task of writing guidelines covers not only the integration of the most recent research, but also the creation of educational tools and implementation programmes for the recommendations. The loop between clinical research, writing of guidelines, and implementing them into clinical practice can then only be completed if surveys and registries are performed to verify that real-life daily practice is in keeping with what is recommended in the guidelines. Such surveys and registries also make it possible to evaluate the impact of implementation of the guidelines on patient outcomes. Guidelines and recommendations should help the physicians to make decisions in their daily practice; however, the ultimate judgment regarding the care of an individual patient must be made by the physician in charge of their care.

2. Introduction

The current estimate of the prevalence of atrial fibrillation (AF) in the developed world is approximately 1.5–2% of the general population, with the average age of patients with this condition steadily rising, such that it now averages between 75 and 85 years. The arrhythmia is associated with a five-fold risk of stroke and a three-fold incidence of congestive heart failure, and higher mortality. Hospitalization of patients with AF is also very common. This arrhythmia is a major cardiovascular challenge in modern society and its medical, social, and economic aspects are all set to worsen over the coming decades. Fortunately a number of valuable treatments have been devised in recent years that may offer some solution to this problem.

In 2010, when the ESC Guidelines for the Management of Atrial Fibrillation were first issued, it was already realized that an update would be necessary in 2012 because, for example, European regulatory approvals of several new drugs were anticipated, such as vernakalant and dabigatran. In addition, reports from major clinical trials of the novel oral anticoagulants, such as AVERROES (Apixaban Versus acetylsalicylic acid (ASA) to Reduce the Rate Of Embolic Stroke in atrial fibrillation patients who have failed or are unsuitable for vitamin K antagonist treatment), ROCKET-AF (Rivaroxaban Once daily oral direct factor Xa inhibition Compared with vitamin K antagonist for prevention of stroke and Embolism Trial in Atrial Fibrillation), and ARISTOTLE (Apixaban for Reduction In STroke and Other Thromboembolic Events in atrial fibrillation), were expected, paving the way for potentially yet more regulatory approvals. What was not necessarily expected was the early discontinuation of the PALLAS (Permanent Atrial fibriLLAtion outcome Study) of dronedarone, nor the reports of hepatotoxicity associated with this drug.

The American College of Cardiology Foundation (ACCF), American Heart Association (AHA), and the Heart Rhythm Society (HRS) have jointly published two major updates, one concerning dronedarone and left atrial ablation, and another focusing on dabigatran. Early in 2012, the American College of Chest Physicians (ACCP) published its 9th version of Antithrombotic Therapy for Atrial Fibrillation, and the Canadian Cardiovascular

<table>
<thead>
<tr>
<th>Classes of recommendations</th>
<th>Definition</th>
<th>Suggested wording to use</th>
</tr>
</thead>
<tbody>
<tr>
<td>Class I</td>
<td>Evidence and/or general agreement that a given treatment or procedure is beneficial, useful, effective.</td>
<td>Is recommended/is indicated</td>
</tr>
<tr>
<td>Class II</td>
<td>Conflicting evidence and/or a divergence of opinion about the usefulness/efficacy of the given treatment or procedure.</td>
<td></td>
</tr>
<tr>
<td>Class IIa</td>
<td>Weight of evidence/opinion is in favour of usefulness/efficacy.</td>
<td>Should be considered</td>
</tr>
<tr>
<td>Class IIb</td>
<td>Usefulness/efficacy is less well established by evidence/opinion.</td>
<td>May be considered</td>
</tr>
<tr>
<td>Class III</td>
<td>Evidence or general agreement that the given treatment or procedure is not useful/effective, and in some cases may be harmful.</td>
<td>Is not recommended</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Level of evidence A</th>
<th>Data derived from multiple randomized clinical trials or meta-analyses.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Level of evidence B</td>
<td>Data derived from a single randomized clinical trial or large non-randomized studies.</td>
</tr>
<tr>
<td>Level of evidence C</td>
<td>Consensus of opinion of the experts and/or small studies, retrospective studies, registries.</td>
</tr>
</tbody>
</table>

Table 1 Classes of recommendations

Table 2 Levels of evidence
In patients 65 years or older, opportunistic screening by pulse palpation, followed by recording of an ECG to verify diagnosis, should be considered for the early detection of AF.14,15

**Recommendation for screening of AF**

<table>
<thead>
<tr>
<th>Recommendations</th>
<th>Class</th>
<th>Level</th>
<th>Ref</th>
</tr>
</thead>
<tbody>
<tr>
<td>Opportunistic screening for AF in patients ≥65 years of age using pulse-taking followed by an ECG is recommended to allow timely detection of AF.</td>
<td>I</td>
<td>B</td>
<td>14, 15</td>
</tr>
</tbody>
</table>

AF = atrial fibrillation; ECG = electrocardiogram.

Class of recommendation.

Level of evidence.

References.

**Key point**

- In patients 65 years or older, opportunistic screening by pulse palpation, followed by an ECG in those with an irregular pulse, is important to detect AF prior to the first stroke.

3. **Stroke and bleeding risk assessment**

It is conventional to divide AF into cases which are described as “valvular” or “non-valvular”. No satisfactory or uniform definition of these terms exists. In this guideline, the term valvular AF is used to imply that AF is related to rheumatic valvular disease (predominantly mitral stenosis) or prosthetic heart valves.

Since the publication of the 2010 ESC Guidelines, additional evidence has strengthened the use of the risk factor-based approach to stroke risk stratification proposed in that guideline, with more focus on the identification of ‘truly low-risk’ patients who do not need any antithrombotic therapy, and more evidence on the use of novel oral anticoagulant drugs (NOACs; see below) as alternatives to dose-adjusted vitamin K antagonist (VKA) therapy [e.g. warfarin, international normalized ratio (INR) 2.0–3.0].16

Stroke risk is a continuum and the predictive value of artificially categorizing AF patients into low, moderate, and high-risk strata only has modest predictive value for identifying the ‘high-risk’ category of patients who would subsequently suffer strokes.17 Until recently, the only oral anticoagulant (OAC) available was the VKA class of drugs (e.g. warfarin) and, despite its limitations, many physicians still prescribed VKA therapy in broadly similar proportions, irrespective of the categorization into low/moderate/high-risk strata; if a VKA was not used, aspirin was often prescribed instead.18,19

The evidence for effective stroke prevention with aspirin in AF is weak, with a potential for harm,20–22 as data indicate that the risk of major bleeding or intracranial haemorrhage (ICH) with aspirin is not significantly different to that of OAC, especially in the elderly.23–25 Given the availability of NOACs, the use of antiplatelet therapy (such as aspirin–clopidogrel combination therapy, or—less effectively—aspirin monotherapy) for stroke prevention in AF should be limited to the few patients who refuse any form of OAC. Aspirin–clopidogrel combination therapy has additional efficacy, compared with aspirin monotherapy, but at additional risk for major bleeding.26 Thus, aspirin monotherapy should be confined to those who refuse any OAC and cannot tolerate aspirin–clopidogrel combination therapy due, for example, to excessive bleeding risk. There is no evidence for the decrease in total or cardiovascular mortality with aspirin (or antiplatelet drugs) in the AF population. Even in non-AF populations, aspirin prophylaxis in people without prior cardiovascular disease does not lead to reductions in either cardiovascular or cancer mortality and the benefits in non-fatal myocardial infarction are further offset by clinically important bleeding events.27

Thus, this guideline strongly recommends a practice shift towards greater focus on identification of ‘truly low-risk’ patients with AF (i.e. ‘age <65 and lone AF, who do not need any antithrombosis therapy’), instead of trying to focus on identifying ‘high-risk’ patients.

To achieve this, it is necessary to be more inclusive (rather than exclusive) of common stroke risk factors as part of any comprehensive stroke risk assessment. Indeed, patients with AF who have stroke risk factor(s) ≥1 are recommended to receive effective stroke prevention therapy, which is essentially OAC with either well-controlled VKA therapy [INR 2–3, with a high percentage of time in the therapeutic range (TTR), for example, at least 70%]28 or one of the NOACs.

Whilst the CHADS2 [Congestive heart failure, Hypertension, Age ≥75, Diabetes, Stroke (doubled)] score is simple,29 most now agree that it does not include many common stroke risk factors and its limitations have been highlighted.30,31 The CHADS2 score was also derived from risk factors identified in datasets of the non-VKA–treated patients in the historical trials of stroke prevention in AF conducted two decades ago. In these trials, fewer than 10% of the patients screened were included, and many stroke risk factors were inconsistently defined or were not systematically recorded.17 For example, vascular disease (not included in the CHADS2 score) is an independent risk factor for stroke in AF and significantly improves the predictive ability of CHADS2.32–34 The risk of stroke also increases from age ≥65 years, with even greater risk at age 75 years or older.32,35,36
Many patients classified as ‘low-risk’ using CHADS2 (score = 0) have stroke rates >1.5%/year,29,36 and a CHADS2 score of 0 does not reliably identify AF patients who are ‘truly low-risk’.37,38

The 2010 ESC Guidelines on AF1 de-emphasized the use of the artificial low-, moderate-, and high-risk strata and recommended a risk factor-based approach defining ‘major’ and ‘clinically relevant’ low-, moderate-, and high-risk strata and recommended a risk factor-based approach defining ‘major’ and ‘clinically relevant’ low-, moderate-, and high-risk strata and recommended a risk factor-based approach defining ‘major’ and ‘clinically relevant’ low-, moderate-, and high-risk strata.25,36,40 Amongst patients with CHADS2 score = 0, the 1-year event rates can range between 0.84% (CHA2DS2-VASc score = 0), 1.75% (CHA2DS2-VASc score = 1), 2.69% (CHA2DS2-VASc score = 2), and 3.2% (CHA2DS2-VASc score = 3).39 Also, CHA2DS2-VASc refines stroke risk assessment in ‘low-risk’ AF patients after ablation.49

AF patients with severe renal failure are at high risk for stroke, but are also at increased risk for death, coronary events and serious bleeding. These patients have not been adequately studied and have been excluded from clinical trials, and their risk assessment is complex.50 There is also the caveat that renal function may not remain static, especially in elderly AF patients with multiple comorbidities and concomitant drug therapies.

Decision-making for thromboprophylaxis needs to balance the risk of stroke against the risk of major bleeding, especially ICH, which is the most feared complication of anticoagulation therapy and confers a high risk of death and disability.51 Until recently, bleeding risk assessment tools were based on complex formulae, with certain risk factors weighted in different ways and/or derived from cohorts of anticoagulated patients, rather than specifically from AF patients.52 Of the available bleeding risk scores, only three have been derived and validated in AF populations: HEMORRHAGES [Hepatic or renal disease, Ethanol abuse, Malig- nancy, Older (age ≥75 years), Reduced platelet count or function, Rebleeding risk, Hypertension (uncontrolled), Anaemia, Genetic factors, Excessive fall risk, and Stroke],53 HAS-BLED [Hyperten- sion, Abnormal renal/liver function, Stroke, Bleeding history or predisposition, Labile INR, Elderly (e.g. age >65, frailty, etc.), Drugs/alcohol concomitantly],54 and ATRIA (AnTicoagulation and Risk Factors In Atrial fibrillation).55

The 2010 ESC Guidelines on AF,1 the Canadian Cardiovascular Society Guidelines (recently updated),9,56 and the consensus document on bleeding in AF, prepared by the European Heart Rhythm Association (EHRA) and the ESC Working Group on Thrombosis,57 all recommended use of the simple bleeding risk assessment score, HAS-BLED, rather than the more complicated...
4. Novel oral anticoagulants

The NOACs for stroke prevention in AF fall into two classes: the oral direct thrombin inhibitors (e.g., dabigatran) and oral direct factor Xa inhibitors (e.g., rivaroxaban, apixaban, etc.). In contrast to VKAs, which block the formation of multiple active vitamin K-dependent coagulation factors (factors II, VII, IX, and X), these drugs block the activity of one single step in coagulation. Another oral factor Xa inhibitor with an ongoing, large phase III trial is edoxaban; this will probably be reported in 2013.

4.1 Dabigatran etexilate

The RE-LY (Randomized Evaluation of Long-term anticoagulant therapy with dabigatran etexilate) trial was a prospective, randomized, open-label, phase III trial comparing two blinded doses of dabigatran etexilate [110 mg b.i.d. (D110) or 150 mg b.i.d. (D150)] with open-label adjusted-dose warfarin, aiming for an INR of 2.0–3.0 (Table 4). For the primary efficacy endpoint of stroke and systemic embolism, D150 was superior to warfarin, with no significant difference in the primary safety endpoint of major bleeding. D110 was non-inferior to warfarin, with 20% fewer major bleeds. Rates of haemorrhagic stroke and ICH were lower with both doses of dabigatran, but gastrointestinal bleeding was significantly increased with D150. There was a non-significant numerical increase (of 28%) in myocardial infarction (MI) with both dabigatran doses. There was a significant reduction in ischaemic stroke, as well as a borderline reduction in all-cause mortality with D150 (P = 0.051) and a significant reduction in vascular mortality (P = 0.04). The rates of discontinuation were higher with D150 (20.7%) and D110 (21.2%), compared with 16.6% with warfarin at 2 years. A post-hoc analysis has reported a significant age interaction, whereby patients aged >75 years had rates of major bleeding similar to warfarin with D110, with a trend towards more bleeding with D150; however, ICH was lower with both doses of dabigatran. The efficacy and safety of dabigatran was consistent across all CHADS2 risk strata. Previous VKA exposure does not influence the benefits of dabigatran at either dose, compared with warfarin.

The concerns over the small increase in MI with dabigatran have prompted a detailed analysis where there was no excess of new angina hospitalizations or revascularization with dabigatran-treated patients, with a vascular mortality and a net clinical benefit in favour of dabigatran. A meta-analysis of seven dabigatran studies (AF, venous thromboembolism, etc.) in over 30 000 patients showed a significant 33% increase in MI, but an 11% reduction in all-cause mortality, when dabigatran was compared to warfarin. However, this may reflect a better protective effect of warfarin against MI.

Based on the results of RE-LY, dabigatran etexilate has been approved by both the Food and Drug Administration (FDA) and the European Medicines Agency (EMA), as well as in many countries worldwide, for prevention of stroke and systemic embolism. The EMA indication is for patients with non-valvular AF at 75 years or age ≥65 years with one of the following: diabetes, coronary artery disease or hypertension. The FDA has approved the 150 mg b.i.d. dose, and the 75 mg b.i.d. dose in severe renal impairment, while the EMA has approved both the 110 mg b.i.d. and 150 mg b.i.d. doses.

4.2 Rivaroxaban

The double-blind ROCKET-AF trial randomized 14 264 high-risk patients with AF to either (i) treatment with rivaroxaban 20 mg o.d. [15 mg daily for those with estimated creatinine clearance (CrCl) 30–49 mL/min] or (ii) warfarin (Table 4). The population
was at considerably higher risk for stroke than in other NOAC AF trials, and the mean TTR was 55% (median 58%), which was lower than in other randomized trials. Rivaroxaban was non-inferior to warfarin for the primary endpoint of stroke and systemic embolism, and the per-protocol on-treatment analysis achieved statistical superiority [relative risk reduction (RRR) 21%, \( P = 0.015 \)] but, using the more conventional intention-to-treat analysis, rivaroxaban was not superior \( (P = 0.12) \). There was no reduction in rates of mortality or ischaemic stroke, but a significant reduction in haemorrhagic stroke and intracranial haemorrhage. The primary safety endpoint was the composite of major- and clinically relevant non-major bleeding, which was not significantly different between rivaroxaban and warfarin but, with rivaroxaban, there was a significant reduction in fatal bleeding, as well as an increase in gastrointestinal bleeds and bleeds requiring transfusion. Premature discontinuation of treatment was more common with rivaroxaban (23.9%) than with warfarin (22.4%).

Rivaroxaban has been approved for stroke prevention in non-valvular AF by both the FDA and the EMA, and in many countries worldwide.

### 4.3 Apixaban

The AVERROES trial\(^2\) randomized 5599 AF patients, who were not suitable candidates for—or were unwilling to take—VKA treatment, to double-blind, double-dummy treatment with either apixaban [5 mg b.i.d. with a dose adjustment to 2.5 mg b.i.d. in patients \( \geq 80 \) years, weight \( \leq 60 \) kg or with a serum creatinine \( \geq 1.5 \) mg/dL \((133 \) \( \mu \)mol/L) or aspirin \((81–324 \) mg/day, with 91% taking \( \leq 162 \) mg/day). After a mean follow-up of 1.1 years, the trial was stopped early, due to a significant 55% reduction in the primary endpoint of stroke or systemic embolism with apixaban compared with aspirin, with no significant difference in rates of major bleeding or ICH between apixaban and aspirin. Apixaban was slightly better tolerated, with rates of permanent discontinuation of study treatments being 20.5% per year in the aspirin group, vs. 17.9% per year in the apixaban group at 2 years \((P = 0.03)\).

The ARISTOTLE trial\(^3\) was a randomized, double-blind, double-dummy, phase III trial comparing apixaban [5 mg b.i.d. with a dose adjustment to 2.5 mg b.i.d. in patients \( \geq 80 \) years, weight \( \leq 60 \) kg or with a serum creatinine \( \geq 1.5 \) mg/dL \((133 \) \( \mu \)mol/L)] with dose-adjusted warfarin aiming for an INR of 2.0–3.0 in 18 201 patients with non-valvular AF (Table 4). There was a significant reduction in the primary efficacy outcome of stroke or systemic embolism by 21% with apixaban compared with warfarin, with a 31% reduction in major bleeding and a significant 11% reduction in all-cause mortality (but not cardiovascular mortality). Rates of haemorrhagic stroke and ICH—but not of ischaemic stroke—were significantly lower in patients treated with apixaban than with warfarin. Gastrointestinal bleeding was similar between the treatment arms. Apixaban was better tolerated than warfarin, with slightly fewer early discontinuations (25.3% vs. 27.5%). Apixaban has not yet gained regulatory approval from the EMA or FDA. It is included in these guidelines because it may be approved shortly after the publication.

### 4.4 Practical considerations\(^4\)

The NOACs so far tested in clinical trials have all shown non-inferiority compared with VKAs, with better safety, consistently limiting the number of ICH. On this basis, this guideline now recommends them as broadly preferable to VKA in the vast majority of patients with non-valvular AF, when used as studied in the clinical trials performed so far. Since there is still limited experience with these agents, strict adherence to approved indications and careful post-marketing surveillance are strongly recommended.

In the absence of head-to-head trials, it is inappropriate to be definitive on which of the NOACs is best, given the heterogeneity of the different trials.\(^77\) Indirect comparison analyses do not suggest profound differences in efficacy endpoints between the NOACs, but major bleeding appears lower with dabigatran 110mg b.i.d. and apixaban.\(^77\) Patient characteristics, drug tolerability, and cost may be important considerations.\(^24\) Some cost-effectiveness data for dabigatran have been published in various healthcare settings, and dabigatran appears to be cost-effective for most patients,\(^78–81\) except in those with very well-controlled INRs. Also, there remain concerns over the applicability of data for the NOACs to very elderly patients with multiple comorbidities, polypharmacy, compliance issues etc., who are often managed by primary care physicians. None of the novel OACs has a specific antidote; dabigatran and apixaban have twice daily dose regimens, and some drug interactions are evident. Patients with severe renal impairment were excluded from the trials and, specifically, dabigatran has a high renal clearance.

The net clinical benefit of VKAs, balancing ischaemic stroke against ICH in patients with non-valvular AF, has been modelled on to stroke and bleeding rates from the Danish nationwide cohort study for dabigatran, rivaroxaban, and apixaban, on the basis of recent clinical trial outcome data for these NOACs.\(^82\) At a CHA\(_2\)DS\(_2\)-VASc score of 1, apixaban and both doses of dabigatran (110 mg b.i.d. and 150 mg b.i.d.) had a positive net clinical benefit while, in patients with CHA\(_2\)DS\(_2\)-VASc score \( \geq 2\), all three NOACs were superior to warfarin, with a positive net clinical benefit, irrespective of bleeding risk.

When switching from a VKA to a NOAC, the INR should be allowed to fall to about 2.0 (there are NOAC-specific and transatlantic differences detailed in the Summaries of Product Characteristics/Package Inserts, but the principle is to judge the waning effect of warfarin against the increasing anticoagulant effect of the NOAC) before starting the NOAC, all of which have rapid clinical benefit, irrespective of bleeding risk.

Compliance and adherence to treatment is crucial, especially since these drugs have a relatively short half-life, such that patients would be left without any anticoagulation protection if more than one dose were missed. All of these drugs have a degree of renal

\(^4\) (Note: Given the multiple considerations on how to safely use NOAC in daily clinical practice in different clinical scenarios, EHRA has prepared additional educational material and a regularly updated website specifically addressing this.)
Table 4  Summary of the clinical trials involving novel anticoagulants vs. warfarin for stroke prevention in non-valvular AF

<table>
<thead>
<tr>
<th>Drug characteristics</th>
<th>Dabigatran (RE-LY)70, 71</th>
<th>Rivaroxaban (ROCKET-AF)3</th>
<th>Apixaban (ARISTOTLE)4</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mechanism</td>
<td>Oral direct thrombin inhibitor</td>
<td>Oral direct factor Xa inhibitor</td>
<td>Oral direct factor Xa inhibitor</td>
</tr>
<tr>
<td>Bioavailability, %</td>
<td>6</td>
<td>60–80</td>
<td>50</td>
</tr>
<tr>
<td>Time to peak levels, h</td>
<td>3</td>
<td>3</td>
<td>3</td>
</tr>
<tr>
<td>Half-life, h</td>
<td>12–17</td>
<td>5–13</td>
<td>9–14</td>
</tr>
<tr>
<td>Excretion</td>
<td>80% renal</td>
<td>2/3 liver, 1/3 renal</td>
<td>25% renal, 75% faecal</td>
</tr>
<tr>
<td>Dose</td>
<td>150 mg b.i.d.</td>
<td>20 mg o.d.</td>
<td>5 mg b.i.d.</td>
</tr>
<tr>
<td>Dose in renal impairment</td>
<td>110 mg b.i.d.</td>
<td>15 mg o.d. (if CrCl 30-49 mL/min)</td>
<td>2.5 mg b.i.d.</td>
</tr>
<tr>
<td>Special considerations</td>
<td>Intestinal absorption is pH-dependent and is reduced in patients taking proton pump inhibitors</td>
<td>Higher levels expected in patients with renal or hepatic failure</td>
<td>Activity lower in fasted patients so should be taken after food</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Study characteristics</th>
<th>Study design</th>
<th>Number of patients</th>
<th>Follow-up period, years</th>
<th>Randomized groups</th>
</tr>
</thead>
<tbody>
<tr>
<td>Study design</td>
<td>Randomized, open-label</td>
<td>18 111</td>
<td>2</td>
<td>Dose-adjusted warfarin vs. blinded doses of dabigatran (150 mg b.i.d., 110 mg b.i.d.)</td>
</tr>
<tr>
<td>Randomized, double-blind</td>
<td>14 264</td>
<td>1.9</td>
<td>Dose-adjusted warfarin vs. rivaroxaban 20 mg o.d.</td>
<td></td>
</tr>
<tr>
<td>Randomized, double-blind</td>
<td>18 201</td>
<td>1.8</td>
<td>Dose-adjusted warfarin vs. apixaban 5 mg b.i.d.</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Baseline patient characteristics</th>
<th>Age, years (mean ± SD)</th>
<th>Male sex, %</th>
<th>CHADS2 (mean)</th>
<th>Outcomes (% per year)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>71.5 ± 8.7 [mean ± SD]</td>
<td>63.6</td>
<td>2.1</td>
<td>Warfarin (n = 6022)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Dabigatran (n = 6076)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Dabigatran 150</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>(n = 6015)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Warfarin (n = 7133)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>(n = 7131)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Apixaban (n = 9081)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>(n = 9120)</td>
</tr>
<tr>
<td></td>
<td>1.69</td>
<td>1.11 (0.66, 0.53–0.82; P for superiority &lt;0.001)</td>
<td>1.53 (0.91, 0.74–1.11; P for non-inferiority &lt;0.001)</td>
<td>2.4</td>
</tr>
<tr>
<td></td>
<td>(HR, 95% CI; P value)</td>
<td>(RR, 95% CI; P value)</td>
<td>(HR, 95% CI; P value)</td>
<td>2.1 (0.88, 0.75–1.03; P for non-inferiority &lt;0.001, P for superiority = 0.12)</td>
</tr>
<tr>
<td></td>
<td>Stroke/systemic embolism</td>
<td>1.6</td>
<td>1.27 (0.79, 0.66–0.95; P &lt;0.001 for non-inferiority, P = 0.01 for superiority)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Ischaemic stroke</td>
<td>1.29</td>
<td>0.97 (0.92, 0.74–1.13; P = 0.42)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Haemorrhagic stroke</td>
<td>0.38</td>
<td>0.24 (0.31, 0.35–0.75; P &lt;0.001)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Major bleeding</td>
<td>3.36</td>
<td>2.13 (0.69, 0.60–0.80; P &lt;0.001)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Intracranial bleeding</td>
<td>0.74</td>
<td>0.80 (0.42, 0.30–0.58; P &lt;0.001)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Extracranial bleeding</td>
<td>2.67</td>
<td>–</td>
<td>–</td>
</tr>
</tbody>
</table>

(continued)
excretion, especially dabigatran. Thus, assessment of renal function (by CrCl) is mandatory for all NOACs, but especially for patients taking dabigatran. Indeed, renal function should be assessed annually in patients with normal (CrCl ≥ 80 mL/min) or mild (CrCl 50–79 mL/min) renal impairment, and perhaps 2–3 times per year in patients with moderate (i.e. creatinine clearance 30–49 mL/min) renal impairment. Dabigatran may also cause dyspepsia, which may perhaps be ameliorated by taking the drug with food or the use of a proton pump inhibitor.

The NOACs do not require dose adjustment on the basis of a specific coagulation test (in contrast to the INR for VKAs). There are non-specific coagulation tests that can be used to check for the presence of an anticoagulation effect (rather than anticoagulation intensity per se). These should not be used for dose adjustment. For dabigatran, the ecarin clotting time and thrombin clotting time are useful tests, and directly reflect thrombin inhibition; however, an activated partial thromboplastin time (aPTT) can also be used (especially in an emergency setting), although the correlation is not linear, particularly at higher concentrations. Rivaroxaban prolongs the prothrombin time (PT) and this might be used as an anti-Xa assay. A better estimate for an anticoagulant effect for the oral Factor Xa inhibitors is an anti-Xa assay.

These novel drugs do not have specific antidotes and management of bleeding is thus largely supportive, given that these drugs have a relatively short (5 to 17 hours) half-life. One small study suggested normalization of coagulation tests with non-activated prothrombin complex concentrate (Cofact®; Sanquin Blood Supply, Amsterdam, the Netherlands) administered to healthy and relatively young individuals taking rivaroxaban, but no effect was seen with dabigatran. Another study found that low-dose FEIBA® (Baxter AG, Vienna, Austria) reversed the anticoagulant activity of rivaroxaban and dabigatran. However, the lack of normalization of coagulation tests does not necessarily correlate with the absence of an anti-haemorrhagic effect, as shown in animal models. Perioperative management is another important consideration. Given the rapid onset and offset of action of dabigatran etexilate, no bridging therapy with low molecular weight heparin (LMWH) is required for the majority of interventions, although this is dependent upon balancing the risks of stroke/thromboembolism vs. bleeding (where the HAS-BLED score has been shown to be useful). Following surgery, NOACs can be restarted as soon as effective haemostasis has been achieved. The NOAC effect will be evident within a few hours after the first dose. The available data suggest that elective cardioversion can be safely performed on dabigatran, with the requirement for 3 weeks of therapeutic anticoagulation pre-cardioversion, the cardioversion performed, and anticoagulation continued for a minimum of 4 weeks post-cardioversion. Event rates were not different between conventional and trans-oesophageal echocardiogram-guided cardioversion; however, drug compliance is crucial for the anticoagulation period peri-cardioversion as, unlike the INR for VKAs, there is no easy means to assess therapeutic anticoagulation. In patients with stroke risk factors or at high risk of recurrence, OAC should be continued long-term, whether with a VKA or a NOAC. No published data on cardioversion with rivaroxaban or apixaban are yet available. There are currently no controlled data on the risk–benefit profile of catheter ablation on uninterrupted NOACs. Ablation of a patient whilst still taking uninterrupted NOACs may carry a small theoretical risk, given the lack of a reversal agent, should a major bleeding complication arise. Data from limited case series suggest that appropriate post-ablation management with dabigatran is associated with a low risk of embolic or bleeding complications, although brief interruption of dabigatran use is associated with more thromboembolic and bleeding complications.

Table 4 Continued

<table>
<thead>
<tr>
<th>Outcomes (% per year)</th>
<th>Dabigatran (RE-LY)86,87</th>
<th>Rivaroxaban (ROCKET-AF)4</th>
<th>Apixaban (ARISTOTLE)4</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gastrointestinal bleeding</td>
<td>1.02</td>
<td>1.12 (1.10, 0.86–1.41; P = 0.43)</td>
<td>3.2 (P &lt; 0.001)</td>
</tr>
<tr>
<td>Myocardial infarction</td>
<td>0.64</td>
<td>0.82 (1.29, 0.96–1.75; P = 0.09)</td>
<td>0.9 (0.81; 0.63–1.06; P = 0.12)</td>
</tr>
<tr>
<td>Death from any cause</td>
<td>4.13</td>
<td>3.75 (0.91, 0.80–1.03; P = 0.13)</td>
<td>1.9 (0.85; 0.70–1.02; P = 0.07)</td>
</tr>
<tr>
<td>% Discontinuation at the end of follow-up</td>
<td>10.2</td>
<td>15.5</td>
<td>14.5</td>
</tr>
<tr>
<td>% Discontinuation/year</td>
<td>5.1</td>
<td>7.8</td>
<td>7.3</td>
</tr>
</tbody>
</table>

AF = atrial fibrillation; b.i.d. = bis in die (twice daily); CHADS2 = congestive heart failure, hypertension, age ≥ 75, diabetes, stroke/TIA [doubled]; CI = confidence interval; CrCl = creatinine clearance; HR = hazard ratio; ITT = intention-to-treat; o.d. = once daily; RR = relative risk; SD = standard deviation; TIA = transient ischaemic attack; VKA = vitamin K antagonist.
Patients taking the NOACs may present with an acute coronary syndrome (ACS) and/or undergo percutaneous coronary intervention (PCI). Concomitant use of antiplatelet therapy with the NOACs significantly increases bleeding risk, as is the case with combining any OAC with antiplatelet therapy. In AF patients at risk of stroke, and irrespective of HAS-BLED score, OAC still confers benefit (reduced mortality and major adverse cardiac events) but with more bleeds. In the absence of robust data, in AF patients with an ACS or PCI/stenting, recommendations based on expert consensus on the management of such patients should be followed, as found within the 2010 ESC Guidelines or current European or North American consensus documents.

Thus, a period of triple therapy is needed (OAC plus aspirin plus clopidogrel), followed by the combination OAC plus single antiplatelet drug and, after one year, management can be with OAC alone in stable patients, where OAC can be adjusted-dose VKA therapy or probably a NOAC. Notably, the only trial where clopidogrel use was not contraindicated was RE-LY, so the data on triple therapy with a NOAC (when given at stroke prevention doses in AF patients) are limited.

A patient taking dabigatran may present with an ACS and, given the non-significant but small numerical increase in MI events with dabigatran compared with warfarin, the concerned clinician may consider the use of a VKA or an alternative NOAC (e.g. rivaroxaban or apixaban). There is little evidence to support this, as the relative effects of dabigatran vs. warfarin on myocardial ischaemic events were consistent in patients with or without a baseline history of MI or coronary artery disease. Although twice-daily low-dose rivaroxaban (2.5 mg or 5 mg b.i.d.) has been used with some benefit in ACS, there are no data on ACS relating to the dose of rivaroxaban used for anticoagulation in AF (20 mg o.d.). Apixaban, used in the stroke prevention dose (5 mg b.i.d.) in the ACS setting in combination with aspirin plus clopidogrel, was associated with no reduction in cardiovascular events but an excess of major bleeding. Patients with AF and stable vascular disease (i.e. no acute events or revascularization for >12 months, whether coronary or peripheral artery disease) can be

---

**Figure 1** Choice of anticoagulant.

**Figure 2** Management of bleeding in patients taking novel oral anticoagulants.
managed with OAC alone, whether as adjusted dose VKA therapy or, probably, a NOAC. In such stable patients, there is no need for concomitant aspirin, which could increase the risk of serious haemorrhage, including intracranial haemorrhage.

Patients taking the NOACs may also present with an acute ischaemic stroke. If the aPTT is prolonged in a patient taking dabigatran (or the PT with rivaroxaban), it should be assumed that the patient is anticoagulated, and thrombolysis should not be administered. Given that dabigatran 150 mg b.i.d. did result in a significant reduction in both ischaemic and haemorrhagic stroke, should the acute ischaemic stroke occur whilst the patient is taking rivaroxaban or apixaban (neither of which

### Recommendations for prevention of thromboembolism in non-valvular AF—general

<table>
<thead>
<tr>
<th>Recommendations</th>
<th>Class†</th>
<th>Level↵</th>
<th>Ref‡</th>
</tr>
</thead>
<tbody>
<tr>
<td>Antithrombotic therapy to prevent thromboembolism is recommended for all patients with AF except in those patients (both male and female) who are at low risk (aged &lt;65 years and lone AF), or with contraindications.</td>
<td>I</td>
<td>A</td>
<td>21, 63, 104, 105, 106</td>
</tr>
<tr>
<td>The choice of antithrombotic therapy should be based upon the absolute risks of stroke/thromboembolism and bleeding and the net clinical benefit for a given patient.</td>
<td>I</td>
<td>A</td>
<td>21, 63, 105</td>
</tr>
<tr>
<td>The CHA2DS2-VASc score is recommended as a means of assessing stroke risk in non-valvular AF.</td>
<td>I</td>
<td>A</td>
<td>25, 36, 39</td>
</tr>
<tr>
<td>In patients with a CHA2DS2-VASc score of 0 (i.e., aged &lt;65 years with lone AF) who are at low risk, with none of the risk factors, no antithrombotic therapy is recommended.</td>
<td>I</td>
<td>B</td>
<td>21, 36, 82</td>
</tr>
</tbody>
</table>
| In patients with a CHA2DS2-VASc score ≥ 2, OAC therapy with:  
  - adjusted-dose VKA (INR 2–3); or  
  - a direct thrombin inhibitor (dabigatran); or  
  - an oral factor Xa inhibitor (e.g. rivaroxaban, apixaban) is recommended, unless contraindicated. | I | A | 3, 4, 70, 82 |
| In patients with a CHA2DS2-VASc score of 1, OAC therapy with:  
  - adjusted-dose VKA (INR 2–3); or  
  - a direct thrombin inhibitor (dabigatran); or  
  - an oral factor Xa inhibitor (e.g. rivaroxaban, apixaban) should be considered, based upon an assessment of the risk of bleeding complications and patient preferences. | IIa | A | 33, 44 |
| Female patients who are aged <65 and have lone AF (but still have a CHA2DS2-VASc score of 1 by virtue of their gender) are low risk and no antithrombotic therapy should be considered. | IIa | B | 33, 44 |
| When patients refuse the use of any OAC (whether VKAs or NOACs), antiplatelet therapy should be considered, using combination therapy with aspirin 75–100 mg plus clopidogrel 75 mg daily (where there is a low risk of bleeding) or—less effectively—aspirin 75–325 mg daily. | IIa | B | 21, 26, 51, 109 |

### Recommendations for prevention of thromboembolism in non-valvular AF—NOACs

<table>
<thead>
<tr>
<th>Recommendations</th>
<th>Class†</th>
<th>Level↵</th>
<th>Ref‡</th>
</tr>
</thead>
</table>
| When adjusted-dose VKA (INR 2–3) cannot be used in a patient with AF where an OAC is recommended, due to difficulties in keeping within therapeutic anticoagulation, experiencing side effects of VKAs, or inability to attend or undertake INR monitoring, one of the NOACs, either:  
  - a direct thrombin inhibitor (dabigatran); or  
  - an oral factor Xa inhibitor (e.g. rivaroxaban, apixaban) is recommended. | I | B | 2, 28, 65, 107 |
| Where OAC is recommended, one of the NOACs, either:  
  - a direct thrombin inhibitor (dabigatran); or  
  - an oral factor Xa inhibitor (e.g. rivaroxaban, apixaban) should be considered rather than adjusted-dose VKA (INR 2–3) for most patients with non-valvular AF, based on their net clinical benefit. | IIa | A | 3, 4, 70, 82 |
| Where dabigatran is prescribed, a dose of 150 mg b.i.d. should be considered for most patients in preference to 110 mg b.i.d., with the latter dose recommended in:  
  - elderly patients, age ≥ 80  
  - concomitant use of interacting drugs (e.g. verapamil)  
  - high bleeding risk (HAS-BLED score ≥ 3)  
  - moderate renal impairment (CrCl 30–49 mL/min). | IIa | B | 85, 96 |
| Where rivaroxaban is being considered, a dose of 20 mg o.d. should be considered for most patients in preference to 15 mg o.d., with the latter dose recommended in:  
  - high bleeding risk (HAS-BLED score ≥ 3)  
  - moderate renal impairment (CrCl 30–49 mL/min). | IIa | C | 3, 108 |
| Baseline and subsequent regular assessment of renal function (by CrCl) is recommended in patients following initiation of any NOAC, which should be done annually but more frequently in those with moderate renal impairment where CrCl should be assessed 2–3 times per year. | IIa | B | 85 |
| NOACs (dabigatran, rivaroxaban, and apixaban) are not recommended in patients with severe renal impairment (CrCl <30 mL/min). | III | A | 3, 24, 70 |
The CHA2DS2-VASc score is better at identifying ‘truly low-risk’ patients with AF and is as good as—and possibly better than—scores such as CHADS2 in identifying patients who develop stroke and thromboembolism.

\[ \text{CHA2DS2-VASc} \]

The HAS-BLED score should be considered as a calculation to assess bleeding risk, whereby a score ≥3 indicates ‘high risk’ and some caution and regular review is needed, following the initiation of antithrombotic therapy, whether with OAC or antiplatelet therapy (LoE = A).

Correctable risk factors for bleeding [e.g. uncontrolled blood pressure, labile INRs if the patient was on a VKA, concomitant drugs (aspirin, NSAIDs, etc.), alcohol, etc.] should be addressed (LoE = B).

Use of the HAS-BLED score should be used to identify modifiable bleeding risks that need to be addressed, but should not be used on its own to exclude patients from OAC therapy (LoE = B).

The risk of major bleeding with antiplatelet therapy (with aspirin–clopidogrel combination therapy and – especially in the elderly – also with aspirin monotherapy) should be considered as being similar to OAC.

\[ \text{HAS-BLED} \]

AF = atrial fibrillation; b.i.d. = bis in die (twice daily); CHA2DS2-VASc = congestive heart failure, hypertension, age ≥75 (doubled), diabetes, stroke (doubled), vascular disease, age 65–74, sex category (female); CrCl i.v. = creatinine clearance; HAS-BLED = hypertension, abnormal renal/liver function (1 point each), stroke, bleeding tendency or predisposition, labile INR if on warfarin, elderly (e.g., age >65), drugs (aspirin, NSAIDs, etc.)/alcohol concomitantly (1 point each); INR = international normalized ratio; i.v. = intravenous; OAC = oral anticoagulant; NOAC = novel oral anticoagulant; NSAID = non-steroidal anti-inflammatory drug; VKA = vitamin K antagonist.

Key points

- The efficacy of stroke prevention with aspirin is weak, with a potential for harm, since the risk of major bleeding (and ICH) with aspirin is not significantly different to that of OAC, especially in the elderly.
- The use of antiplatelet therapy (as aspirin–clopidogrel combination therapy or—less effectively—aspirin monotherapy for those who cannot tolerate aspirin–clopidogrel combination therapy) for stroke prevention in AF should be limited to the few patients who refuse any form of OAC.
- The HAS-BLED score allows clinicians to make an informed assessment of bleeding risk and, importantly, makes them think of the correctable risk factors for bleeding. In patients with a HAS-BLED score ≥3, caution and regular review are recommended, as well as efforts to correct the potentially reversible risk factors for bleeding. A high HAS-BLED score per se should not be used to exclude patients from OAC therapy.
- The NOACs offer better efficacy, safety, and convenience compared with OAC with VKAs. Thus, where an OAC is recommended, one of the NOACs—either a direct thrombin inhibitor (dabigatran) or an oral factor Xa inhibitor (e.g. rivaroxaban, apixaban)—should be considered instead of adjusted-dose VKA (INR 2–3) for most patients with AF.
- There is insufficient evidence to recommend one NOAC over another, although some patient characteristics, drug compliance and tolerability, and cost may be important considerations in the choice of agent.

5. Left atrial appendage closure

5.1 Rationale and techniques for left atrial appendage closure

The left atrial appendage (LAA) is considered the main (but not the only) site of thrombus formation inducing ischaemic stroke.
in patients suffering from AF. Trans-oesophageal echocardiography detects most thrombi in the LAA and low stroke rates are reported in patients in whom the LAA has been surgically removed (although these patients were also reverted to sinus rhythm by various surgical techniques). Indeed, surgical excision or stapling of the LAA is widely performed as a concomitant procedure during open heart surgery. More recently, minimally invasive epicardial techniques and interventional trans-septal techniques have been developed for occlusion of the LAA orifice to reduce the stroke risk. These devices/procedures may provide an alternative to OAC for AF patients at high risk for stroke but with contraindications for chronic OAC and, if the efficiency of LAA closure can be conclusively shown, to potentially replace long-term OAC.

5.2 Results of left atrial appendage closure

Although clinically applied for decades, there is no conclusive evidence that surgical LAA excision or occlusion reduces stroke risk in AF patients, due to a lack of large, controlled trials with systematic follow-up. Furthermore, there are data to suggest that not all strokes in AF patients are cardio-embolic or due to AF, and the LAA is probably not the only left atrial region where thrombi can potentially originate. This suggests that there may be a need for antithrombotic therapy in AF patients, even after removal or closure of the LAA.

Data from retrospective or observational studies in different patient populations have shown inconsistent results of surgical LAA excision or occlusion. In addition, no conclusive data are available on the best surgical technique for performing LAA closure. Risks of surgical LAA excision include major bleeding and incomplete LAA occlusion with residual stroke risk.

Non-randomized observational studies, involving relatively small numbers of patients, have shown the feasibility of percutaneous LAA occlusion. Currently, two self-expanding devices, the WATCHMAN (Boston Scientific, Natick, MA, USA) and the Amplatzer Cardiac Plug (St. Jude Medical, St Paul, MN, USA), that are trans-septally placed in the LAA, are available for clinical use in Europe, while their evaluation in controlled trials is still in process. The WATCHMAN LAA system for embolic PROTECTION in patients with Atrial Fibrillation (PROTECT AF) trial randomized 707 eligible patients either to percutaneous closure of the LAA, using the WATCHMAN device, or to OAC (INR range 2–3; control; n = 244). Patients randomized to LAA occlusion were treated with OAC for 45 days after the procedure, followed by dual platelet inhibition for six months and aspirin alone as chronic therapy. The primary efficacy event rate (composite endpoint of stroke, cardiovascular death, and systemic embolism) in the LAA occlusion group was non-inferior to patients treated with OAC. There was a high rate of adverse events in the intervention group, mainly due to peri-procedural complications. Many of the adverse events in the intervention group occurred early in the trial, indicative of an operator learning curve. The Continued Access to PROTECT AF (CAP) registry is following patient outcomes beyond the end of enrolment and demonstrates a “learning curve effect” with reduced complication rates after the end of the trial. A second randomized trial, PREVAIL (Prospective Randomized EVALuation of the Watchman LAA closure device In patients with atrial fibrillation vs. Long-term warfarin therapy), is currently enrolling patients.

In a feasibility and safety study, LAA occlusion with the Amplatzer Cardiac Plug was attempted in 137 of 143 patients, and was successfully performed in 132 (96%). Serious complications occurred in 10 (7.0%) patients. A randomized prospective study with the device is currently under way (Amplatzer Cardiac Plug Trial).

Although the concept of LAA closure seems reasonable, the evidence of efficacy and safety is currently insufficient to recommend these approaches for any patients other than those in whom long-term OAC is contraindicated. However, in the absence of controlled clinical data this recommendation is based on expert consensus only. Additional, adequately powered, randomized studies in patients with high stroke risk and long-term follow-up, comparing interventional/percutaneous/surgical LAA closure with OAC therapy including NOAC drugs, are needed for adequate assessment of such techniques. The need for lifelong aspirin treatment after placement of LAA closure devices, and the significant bleeding risk with aspirin, may weigh against preference for interventional LAA occlusion. At present, interventional LAA closure is not indicated simply as an alternative to OAC therapy to reduce stroke risk.

**Recommendations for LAA closure/occlusion/excision**

<table>
<thead>
<tr>
<th>Recommendations</th>
<th>Class a</th>
<th>Level b</th>
<th>Ref c</th>
</tr>
</thead>
<tbody>
<tr>
<td>Interventional, percutaneous LAA closure may be considered in patients with a high stroke risk and contraindications for long-term oral anticoagulation.</td>
<td>IIb</td>
<td>B</td>
<td>115, 118</td>
</tr>
<tr>
<td>Surgical excision of the LAA may be considered in patients undergoing open heart surgery.</td>
<td>IIb</td>
<td>C</td>
<td></td>
</tr>
</tbody>
</table>

LAA = left atrial appendage.

aClass of recommendation.

bLevel of evidence.
cReferences.

**Key point**

- Interventional percutaneous occlusion/closure of the LAA has a role in patients with thromboembolic risk who cannot be managed in the long-term using any form of OAC.

6. Cardioversion with pharmacological agents

Since the publication of the 2010 ESC Guidelines, a new intravenous antiarrhythmic agent, vernakalant, has been approved for pharmacological cardioversion of AF of ≤7 days, or ≤3 days for patients after cardiac surgery. This update only includes recommendations that have been modified since 2010.
Vernakalant acts preferentially in the atria by blocking several ion channels, resulting in prolongation of atrial refractoriness and rate-dependent slowing of atrial conduction, but has little impact on currents involved in ventricular repolarisation. Vernakalant has a rapid onset of action and a mean elimination half-life of 3–5 hours.

6.1 Clinical evidence for vernakalant

The efficacy of vernakalant was investigated in one dose-finding study, three medium-sized randomized placebo-controlled phase III clinical studies, one randomized clinical trial with amiodarone as an active comparator, and a phase IV open-label study (Table 5). In phase III and IV studies, vernakalant was administered as a 10-min infusion of 3 mg/kg and, if AF persisted after 15 minutes, a second infusion of 2 mg/kg was given. Patients enrolled in the vernakalant studies were primarily men (68%), with a mean age of 63 years, with approximately half of the patients over 65 years.

In the Atrial arrhythmia Conversion Trials (ACT), vernakalant was significantly more effective than placebo in converting AF of ≤7 days (51.7% and 51.2% vs. 4% and 3.6%, respectively). Meta-analysis of the efficacy of vernakalant compared favourably with older antiarrhythmic agents for rapid cardioversion (within 2 hours). Vernakalant retained its efficacy in subgroups of patients with associated cardiovascular pathologies such as ischaemic heart disease and hypertension. Specifically, in 274 patients with ischaemic heart disease (41% with previous MI) included in all studies, the placebo-subtracted efficacy of vernakalant was 45.7%, compared with 47.3% in those without ischaemic heart disease, with no excess in adverse events such as hypotension, bradycardia, and ventricular arrhythmias. However, there was a trend towards a reduced benefit in patients with heart failure. Over 95% of patients who converted to sinus rhythm after receiving vernakalant injection remained in sinus rhythm at 24 hours. In the pooled ACT I and –III trials, 76% of patients in the vernakalant group received concomitant rate-control treatment with beta-blockers, calcium antagonists or digoxin, and 24% were receiving antiarrhythmic drug therapy. There was no difference in adverse events.

Vernakalant cardioverted 47% of patients enrolled in ACT II with postoperative AF after cardiac surgery, compared with 14% who converted spontaneously on placebo, with a median time to conversion of 12 min. Vernakalant was ineffective in converting AF of more than 7 days duration or typical atrial flutter. Conversion of AF to atrial flutter was observed in 8.6–12.7% of patients treated with vernakalant, one-third of whom subsequently converted to sinus rhythm.

6.2 Safety of vernakalant

The most common side effects of vernakalant were taste alterations (~30%), sneezing (16%), paraesthesiae (10%), and nausea (9%), which usually resolved within 5–15 minutes. Serious adverse events were reported at similar rates for vernakalant and placebo (4.1% vs. 3.9%). Transient hypotension occurred in about 5–7% of patients treated with vernakalant, with the blood pressure returning to baseline after approximately 15–20 minutes. Hypotension within the first 2 hours was most common in patients with heart failure (16.1%), leading to discontinuation of treatment in 2.9%. Bradycardia was more common with vernakalant than placebo but seldom led to drug discontinuation (0.5%). There was no excess in ventricular arrhythmia events compared with placebo (5.3% vs. 6.3% at 2 hours and 12.5% vs. 16.5% at 24 hours after the start of treatment) and no drug-related torsades de pointes. However, in patients with heart failure, non-sustained ventricular arrhythmias (usually ventricular triplets and salvos) occurred more often on treatment (7.3% vs. 1.6% on placebo). The QTc interval was prolonged by 20–25 ms and the QRS complex was increased by about 8 ms after infusion of vernakalant.

The drug is contraindicated in patients with hypotension (systolic blood pressure <100 mmHg), ACS within 30 days, NYHA class III and IV heart failure, severe aortic stenosis, and QT interval prolongation (uncorrected QT >440 ms), and should be used with caution in

Recommendations for pharmacological cardioversion of recent-onset AF

<table>
<thead>
<tr>
<th>Recommendations</th>
<th>Class a</th>
<th>Level b</th>
<th>Ref c</th>
</tr>
</thead>
<tbody>
<tr>
<td>When pharmacological cardioversion is preferred and there is no or minimal structural heart disease, intravenous flecainide, propafenone, ibutilide, or vernakalant are recommended.</td>
<td>I</td>
<td>A</td>
<td>120, 121, 123, 124, 126, 127, 131–134</td>
</tr>
<tr>
<td>In patients with AF ≤7 days and moderate structural heart disease [but without hypotension &lt;100 mm Hg, NYHA class III or IV heart failure, recent (&lt;30 days) ACS, or severe aortic stenosis], intravenous vernakalant may be considered. Vernakalant should be used with caution in patients with NYHA class I–II heart failure.</td>
<td>IIb</td>
<td>B</td>
<td>120, 121, 124, 128</td>
</tr>
<tr>
<td>Intravenous vernakalant may be considered for cardioversion of postoperative AF ≤3 days in patients after cardiac surgery.</td>
<td>IIb</td>
<td>B</td>
<td>122</td>
</tr>
</tbody>
</table>

ACS = acute coronary syndrome; AF = atrial fibrillation; LoE = level of evidence; NYHA = New York Heart Association.

aClass of recommendation.

bLevel of evidence.

cReferences.
### Table 5  Summary of clinical studies of vernakalant in AF/flutter

<table>
<thead>
<tr>
<th>Study</th>
<th>Design</th>
<th>Number of patients</th>
<th>Underlying heart disease</th>
<th>AF duration</th>
<th>Time to conversion (median, minutes)</th>
<th>Conversion to sinus rhythm vs. placebo or control (primary endpoint)</th>
<th>Other efficacy outcomes</th>
</tr>
</thead>
<tbody>
<tr>
<td>CRAFT</td>
<td>Double-blind, dose-ranging, placebo-controlled, phase II</td>
<td>56 Vernakalant: n = 18; Vernakalant 0.5 + 1 mg/kg: n = 18 Placebo: n = 20</td>
<td>Hypertension, 57%; diabetes, 23%</td>
<td>AF 3–72 h (mean, 11.5–19.5 h)</td>
<td>14</td>
<td>61% (vernakalant 2 + 3 mg) vs. 5% (primary endpoint)</td>
<td>Conversion rate for vernakalant 0.5 + 1 mg/kg: 11%</td>
</tr>
<tr>
<td>ACT I</td>
<td>Double-blind, placebo-controlled, phase III</td>
<td>336 Vernakalant: n = 221 Placebo: n = 115</td>
<td>Hypertension, 42.5%; ischaemic heart disease, 20.2%; myocardial infarction, 9.8%; heart failure, 14.9%; diabetes, 8%</td>
<td>AF 3 h–45 days (median, 41.8–59.1 h) AF 3 h–7 days (median, 28.2–28.4 h); n = 220 AF 8–45 days (median, 19.4–25.5 days); n = 116</td>
<td>11</td>
<td>51.7% vs. 4%, P &lt;0.001</td>
<td>76% converted after a single dose. Conversion rates for patients with AF ≤48 h: 62.1% vs. 4.9%, P &lt;0.001; with AF &gt;7 days: 7.9% vs. 0%, P = 0.09</td>
</tr>
<tr>
<td>ACT II</td>
<td>Double-blind, placebo-controlled, phase III</td>
<td>160 Vernakalant: n = 106 Placebo: n = 54</td>
<td>CABG, 67%; valvular surgery, 23.6%; combined, 9.3%. Hypertension, 69.5%; ischaemic heart disease, 60%; heart failure, 31.6%</td>
<td>AF 3–48 h (median, 19.4–25.5 days)</td>
<td>12</td>
<td>47% vs. 14%, P &lt;0.001</td>
<td>75% converted after a single dose. Patients with flutter converted: 0/6 vs. 1/4</td>
</tr>
<tr>
<td>ACT III</td>
<td>Double-blind, placebo-controlled, phase III</td>
<td>265 Vernakalant: n = 134 Placebo: n = 131</td>
<td>Hypertension, 43.9%; ischaemic heart disease, 11.8%; myocardial infarction, 6.5%; heart failure, 19.8%; diabetes, 8.4%</td>
<td>AF 3–45 days (median, 38.3 h) AF 3–7 days: n = 172 AF 8–45 days: n = 70 Atrial flutter: n = 23</td>
<td>8</td>
<td>51.2% vs. 3.6%, P &lt;0.001</td>
<td>81.8% converted after a single dose. Conversion rates for patients with AF &gt;7 days: 9% vs. 3%, P = 0.33; with flutter: 7.1% (1/14) vs. 0% (0/9)</td>
</tr>
<tr>
<td>ACT IV</td>
<td>Open-label, phase IV</td>
<td>167</td>
<td>Hypertension, 44%; ischaemic heart disease, 8%; heart failure, 11%</td>
<td>AF 3–45 days (median, 17.7 h)</td>
<td>14</td>
<td>50.9%</td>
<td>Conversion rates for patients with AF ≤48 h: 57.9% vs. AF &gt;7 days: 11.6%</td>
</tr>
<tr>
<td>AVRO</td>
<td>Double-blind, active-controlled (i.e. amiodarone), phase III</td>
<td>232 Vernakalant: n = 116 Amiodarone: n = 116</td>
<td>Hypertension, 71.6%; ischaemic heart disease, 22.4%; myocardial infarction, 8.2%; heart failure, 19.8%; NYHA I, 45.7%; NYHA II, 54.3%; valvular heart disease, 6.6%</td>
<td>AF 3–48 h (mean, 17.7 h)</td>
<td>11</td>
<td>51.7% vs. 5.2%, P &lt;0.0001</td>
<td>Reduction in symptoms at 2 h reported by 53.4% patients in the vernakalant group vs. 32.8% in the amiodarone group, P = 0.0012</td>
</tr>
<tr>
<td>Scene 2</td>
<td>Double-blind, controlled, phase II/III</td>
<td>54 Vernakalant: n = 39 Placebo: n = 15</td>
<td>–</td>
<td>Atrial flutter 3–45 days (mean, 98–178 h)</td>
<td>–</td>
<td>3% vs. 0%, P = 0.45</td>
<td>–</td>
</tr>
</tbody>
</table>

ACT = Atrial arrhythmia Conversion Trial; AF = atrial fibrillation; AVRO = A prospective, randomized, double-blind, active-controlled, superiority study of Vernakalant vs. amiodarone in Recent Onset atrial fibrillation; CRAFT = Controlled Randomized Atrial Fibrillation Trial; NYHA = New York Heart Association.

In the dose-finding CRAFT study, two doses of vernakalant were used: 0.5 mg/kg 10-min bolus followed by 1 mg/kg bolus or 2 mg/kg 10-min bolus followed by 3 mg/kg bolus if AF was present 30 min after the first infusion. In the subsequent ACT I–IV, AVRO, and Scene 2 studies, a 10-min infusion of 3 mg/kg was given followed by a 2 mg/kg bolus if AF did not terminate within 15 min after the first infusion.

The primary endpoint in the ACT I–IV and Scene 2 studies was the proportion of patients with AF of 3–7 days duration or atrial flutter, respectively, who converted to sinus rhythm within 90 min of drug initiation; the primary endpoint in the CRAFT study was the proportion of patients with AF of 3–72 h duration who converted to sinus rhythm during infusion or within 30 min after the last infusion; the primary endpoint in the AVRO study was the proportion of patients with AF of 3–48 h duration who converted to sinus rhythm within 90 min of drug initiation.

No reports of torsades de pointes within 24 hours of treatment; three cases of torsades de pointes at 32 h, 16, and 17 days, respectively, after vernakalant infusion (drug-unrelated). One other trial (ACT V) was terminated prematurely after one death associated with vernakalant infusion. No details are available.
patients with NYHA I or II heart failure because of increased risk of hypotension. At present, vernakalant should be avoided in patients with reduced LVEF (≤ 35%) because of limited experience.

The integration of vernakalant into the general schema for pharmacological and electrical cardioversion is shown in Figure 3.

Key Points

- Vernakalant is effective in cardioversion of patients with AF ≤ 7 days or AF ≤ 3 days after cardiac surgery and provides a rapid antiarrhythmic effect with approximately 50% of patients converting within 90 minutes after the start of treatment and a median time to conversion of 8–14 minutes.
- Vernakalant is administered as a 10-minute infusion of 3 mg/kg and, if AF persists after 15 minutes, a second infusion of 2 mg/kg can be given.
- Vernakalant has a satisfactory safety profile in patients with minimal-to-moderate heart disease, including ischaemic heart disease, but should be used with caution in haemodynamically stable patients with NYHA class I and II heart failure, because of increased risk of hypotension and non-sustained ventricular arrhythmias in these patients.
- Vernakalant is contraindicated in patients with hypotension <100 mmHg, recent (<30 days) acute coronary syndrome, NYHA class III and IV heart failure, severe aortic stenosis, and QT interval prolongation (uncorrected QT > 440 ms).

7. Oral antiarrhythmic drug therapy

7.1 Upstream therapy

In the last several years, a number of trials investigating upstream therapy for prevention of AF have been reported. All of the recent placebo-controlled, double-blind trials with angiotensin-receptor blockers (ARBs) and the majority of trials with polyunsaturated fatty acids failed to show convincing results. There is now very little reason to consider the use of such therapy for the prevention of AF recurrence in patients with little or no underlying heart disease. It may still be justified to co-prescribe an ARB or an angiotensin-converting enzyme inhibitor with an antiarrhythmic drug to increase the likelihood of maintaining sinus rhythm after cardioversion.

7.2 Principles of antiarrhythmic drug therapy

Oral antiarrhythmic drug therapy can be considered for the treatment of recurrent (paroxysmal and persistent) AF. Several meta-analyses and systematic reviews have confirmed antiarrhythmic efficacy whilst raising signals of concern related to adverse events and mortality. For this reason, it is important to emphasise that antiarrhythmic drug therapy should only be offered to control resistant symptoms due to recurrent AF and that a safety-
<table>
<thead>
<tr>
<th>Study</th>
<th>Patients (n)</th>
<th>Patient characteristics</th>
<th>Dose of dronedarone</th>
<th>Placebo controlled</th>
<th>Primary endpoint</th>
<th>Follow-up (months)</th>
<th>Outcome</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>DAFNE152</td>
<td>199</td>
<td>Post cardioversion</td>
<td>400 mg b.i.d. 600 mg b.i.d. 800 mg b.i.d.</td>
<td>Yes</td>
<td>Time to first AF recurrence</td>
<td>6</td>
<td>Dronedarone 400 mg b.i.d. significantly prolonged median time to first AF recurrence vs. placebo: 60 vs. 5.3 days (P = 0.026); RRR 35% (95% CI 28–72%; P = 0.001)</td>
<td>Higher doses were ineffective and were associated with discontinuation rates of 7.6% and 22.6%; conversion rates were 5.8%, 8.2%, and 14.8% vs. 3.1% on placebo</td>
</tr>
<tr>
<td>EURIDIS153</td>
<td>615</td>
<td>Paroxysmal or persistent AF (post cardioversion)</td>
<td>400 mg b.i.d.</td>
<td>Yes</td>
<td>Time to first AF recurrence</td>
<td>12</td>
<td>Median time to first AF recurrence was 41 days on dronedarone vs. 96 days on placebo (P = 0.01)</td>
<td>Ventricular rates during AF recurrence were significantly lower on dronedarone</td>
</tr>
<tr>
<td>ADONIS153</td>
<td>630</td>
<td>Paroxysmal or persistent AF (post cardioversion)</td>
<td>400 mg b.i.d.</td>
<td>Yes</td>
<td>Time to first AF recurrence</td>
<td>12</td>
<td>Median time to first AF recurrence was 59 days on dronedarone vs. 158 days on placebo (P = 0.002)</td>
<td>Dronedarone reduced ventricular rates during AF recurrence vs. placebo</td>
</tr>
<tr>
<td>ERATO18</td>
<td>630</td>
<td>Permanent AF with ventricular rates &gt;80 b.p.m. on rate-controlling therapy</td>
<td>400 mg b.i.d.</td>
<td>Yes</td>
<td>Mean 24-h ventricular rate at 2 weeks</td>
<td>6</td>
<td>Ventricular rates were 12 b.p.m. lower on dronedarone vs. placebo</td>
<td>Peak heart rates during exercise were 24 b.p.m. lower on dronedarone vs. placebo</td>
</tr>
<tr>
<td>ANDROMEDA18</td>
<td>67 (1000 planned)</td>
<td>Congestive heart failure; EF &lt;0.35%</td>
<td>400 mg b.i.d.</td>
<td>Yes</td>
<td>All-cause mortality</td>
<td>Median, 2</td>
<td>Stopped early because of increased mortality in the dronedarone arm: total mortality n = 25 in dronedarone group, n =12 in placebo group; cardiovascular mortality n = 24 in dronedarone group, 9 in placebo group</td>
<td></td>
</tr>
<tr>
<td>ATHENA40</td>
<td>4628</td>
<td>Paroxysmal or persistent AF with risk factors</td>
<td>400 mg b.i.d.</td>
<td>Yes</td>
<td>All-cause mortality and hospitalizations for cardiac causes</td>
<td>21 ± 5</td>
<td>Dronedarone reduced the primary endpoint vs. placebo by 24% (P &lt;0.001)</td>
<td>CV hospitalizations, CV mortality and hospitalizations for AF and for ACS reduced</td>
</tr>
<tr>
<td>DIONYSOS155</td>
<td>504</td>
<td>Persistent AF</td>
<td>400 mg b.i.d.</td>
<td>Amiodarone</td>
<td>AF recurrence or premature study drug discontinuation</td>
<td>6</td>
<td>Amiodarone superior to dronedarone (P &lt;0.001)</td>
<td></td>
</tr>
<tr>
<td>PALLAS1</td>
<td>3236 (10 800 planned)</td>
<td>Permanent AF with CV risk factors</td>
<td>400 mg b.i.d.</td>
<td>Yes</td>
<td>1. Co-primary = composite of stroke, MI, SE; CV death 2. Co-primary = composite of first unplanned CV hospitalization or death</td>
<td>Median, 3.5</td>
<td>Stopped early because of excess events in the dronedarone group: total mortality n = 25 in dronedarone group, n = 13 in placebo group; cardiovascular mortality n = 21 in dronedarone group, n = 10 in placebo group</td>
<td>Only 64 of planned 844 outcome events occurred</td>
</tr>
</tbody>
</table>

ACS = acute coronary syndrome; ADONIS = American-Australian-African trial with DronedarOnE in atrial fibrillation or flutter for the maintenance of Sinus rhythm; AF = atrial fibrillation; ANDROMEDA = Antiarrhythmic trial with DROnedarone in Moderate to severe heart failure Evaluating morbidity Decrease; ATHENA = A placebo-controlled, doubleblind, parallel arm Trial to assess the efficacy of dronedarone 400 mg b.i.d. for the prevention of cardiovascular Hospitalization or death from any cause in patientS with Atrial fibrillation/atrial flutter; b.i.d. = bis in die (twice daily); b.p.m. = beats per minute; CI = confidence interval; CV = cardiovascular; DAFNE = Dronedarone Atrial Fibrillation study after Electrical cardioversion; DIONYSOS = Randomized Double blind trial to evaluate efficacy and safety of drOnedarone (400 mg b.i.d.) vs. amiodarOnE (600 mg q.d. for 28 dAYs, then 200 mg q.d. thereafter) for at least 6 mOnths for the maintenance of Sinus rhythm in patients with atrial fibrillation; EF = ejection fraction; ERATO = Efficacy and safety of dRonedArone for The cOnrol of ventricular rate during atrial fibrillation; EURIDIS = EURopean trial In atrial fibrillation or flutter patients receiving Dronedarone for the maintenance of Sinus rhythm; MI = myocardial infarction; RRR = relative risk reduction; SE = systemic embolism.
first principle should prevail. In this regard, the finding that persistent episodes of AF can be reduced or delayed by short-term (4 weeks post cardioversion) antiarrhythmic therapy may allow shorter treatment durations.

Antiarrhythmic drug therapy for AF has generally been given as long-term therapy. A recently published trial, the Flec-SCL (Flecainide Short Long) trial\textsuperscript{145} randomized 635 patients (mean age 64 years, 64% male, 97% preserved left ventricular ejection fraction, 6% coronary artery disease, mean left atrial diameter 47 mm) to (i) no antiarrhythmic drug therapy (81 patients), (ii) long-term therapy (263 patients), or (iii) to short-term antiarrhythmic drug therapy limited to four weeks after cardioversion (261 patients). The trial tested the hypothesis that short-term therapy was non-inferior to long-term therapy. Patients were followed for six months by daily telemetric ECG recording for the primary outcome of persistent AF or death. The trial demonstrated that short-term therapy conveyed a slightly inferior—but still effective—antiarrhythmic action, estimated at 80% of the effect of long-term therapy six months after cardioversion. One prior trial compared episodic amiodarone treatment to continuous treatment, assessing a composite primary outcome containing efficacy and safety events. In that trial, episodic amiodarone was not nearly as effective as continuous amiodarone.\textsuperscript{146} Based on that trial and on the pharmacokinetics of amiodarone, especially its long half-life, amiodarone does not seem to be suitable for short-term antiarrhythmic drug therapy.\textsuperscript{147} Taken as a whole, the available information suggests that short-term antiarrhythmic drug therapy after cardioversion should not be the default type of treatment and should not be considered with amiodarone, but may be useful in patients who are either at high risk for drug-induced adverse effects or for patients with infrequent recurrences of AF.

### 7.3 Update on dronedarone

Dronedarone is a benzofuran derivative, structurally related to amiodarone, which has recently been approved for the treatment of paroxysmal or persistent AF. Dronedarone is a ‘multichannel blocker’ that inhibits sodium and potassium channels, shows a non-competitive antiadrenergic activity, and has calcium antagonist properties. The drug is more effective in maintaining sinus rhythm than placebo but inferior to amiodarone in that respect (Table 6). In the ATHENA (A placebo-controlled, double-blind, parallel arm Trial to assess the efficacy of dronedarone 400 mg b.i.d. for the prevention of cardiovasular Hospitalization or death from any cause in patients at moderate risk for cardiovascular events, who had paroxysmal or persistent AF, dronedarone was associated with a significant reduction in cardiovascular outcome events, including the composite of unplanned cardiovascular hospitalizations and all-cause mortality. Other analyses demonstrated a significant reduction in arrhythmic mortality, cardiovascular mortality (including arrhythmic mortality), and stroke (Table 6).

A similar but unexpected reduction in outcome events was also seen in a small population of patients that remained in AF throughout the trial. A large randomized trial to compare dronedarone against placebo in patients with permanent AF was therefore undertaken. The results were recently reported of the PALLAS (Permanent Atrial fibrillaTion outcome Study) trial,\textsuperscript{5} in which patients with permanent AF (defined for inclusion in the trial as >6 months) and cardiovascular risk factors were randomized to receive dronedarone 400 mg b.i.d. or matching placebo on top of best medical therapy (Table 6).

The trial planned to enrol 10 800 patients but was stopped prematurely by the Data Monitoring Committee after enrolment of 3236 patients, due to an increase in cardiovascular events—including cardiovascular mortality—in the dronedarone arm, compared with the control group. The first co-primary study outcome (composite of stroke, MI, systemic embolism, and cardiovascular death) was observed in 43 patients receiving dronedarone and 19 receiving placebo [hazard ratio (HR) 2.29; 95% CI, 1.34–3.94; \(P = 0.002\)].

The secondary co-primary study outcome (first unplanned cardiovascular hospitalization or death) occurred in 127 patients receiving dronedarone and 67 patients on placebo (HR 1.95, 95% CI 1.45–2.62; \(P < 0.001\)). There were 21 deaths from cardiovascular causes in the dronedarone group and 10 in the placebo group (HR 2.11; 95% CI 1.00–4.49; \(P = 0.046\)), including sudden death, probably from an arrhythmia in 13 patients and four patients, respectively (HR 3.26; 95% CI 1.06–10.00; \(P = 0.03\)). Stroke occurred in 23 patients in the dronedarone group and 10 in the placebo group (HR 2.32; 95% CI 1.11–4.88; \(P = 0.02\)). Hospitalization for heart failure occurred in 43 patients in the dronedarone group and 24 in the placebo group (HR 1.81; 95% CI 1.10–2.99; \(P = 0.02\)).

The reasons why the PALLAS results differed so much from ATHENA are not entirely clear. PALLAS patients had greater cardiovascular disease burden and obviously had permanent AF. There are no other antiarrhythmic drug trials in permanent AF; hence the results of PALLAS cannot be compared with other studies. From a methodological point of view, PALLAS had only collected 64 of the planned 844 primary study endpoints before it was terminated. Moreover, mortality in the placebo group of PALLAS was lower than that in the dronedarone group in ATHENA, despite more cardiovascular disease burden in the former study.

As a consequence of the PALLAS trial, patients with permanent AF should not be treated with dronedarone, particularly those with a significant cardiovascular disease burden. The drug can still be used in patients with paroxysmal or persistent AF after cardioversion. The revised European Summary of Product Characteristics for the drug advises that dronedarone management be supervised by a ‘specialist’, i.e. hospital or office-based staff familiar with the use of antiarrhythmic drugs, and it is clear that it should not be initiated in general or family practice. Subsequent monitoring should also include input from an appropriate specialist. Currently there is European regulatory approval for the use of dronedarone for the maintenance of sinus rhythm after cardioversion. Cardioversion may be spontaneous or induced and the patient may or may not be taking dronedarone at the time of cardioversion. A recurrence of AF that persists requires that the physician and patient choose whether to achieve sinus rhythm (e.g. by electrical cardioversion), in which case therapy with dronedarone may be maintained, or to leave the patient in AF, which de facto becomes ‘permanent’ in nature, in which case treatment with dronedarone should be stopped.

In the most recent EMA update on dronedarone, the drug was contraindicated in patients with unstable haemodynamic conditions, with a history of (or current) heart failure or left ventricular...
dysfunction. For patients in NYHA functional class III or IV, there is evidence from the ANDROMEDA (ANtiarrhythmic trial with DROnedarone in Moderate-to-severe congestive heart failure Evaluating morbidity DecreAse) trial that these patients may derive harm from dronedarone therapy. On the other hand, in patients with NYHA class I or II heart failure, or with HF-PEF, there is no clear scientific evidence for harmful effects of the drug. There was no clear signal from the subgroup analysis of PALLAS that the extent of heart failure (NYHA class) or degree of left ventricular systolic dysfunction (left ventricular ejection fraction) was relevant to any PALLAS endpoint, including heart failure hospitalizations or events. On the other hand, PALLAS recruited a high proportion of patients with a history of heart failure and various degrees of cardiac decompensation, except for NYHA class IV. Heart failure events in PALLAS were more common in patients with underlying coronary artery disease, but the statistical validity of this subgroup analysis is uncertain. Use of dronedarone as an antiarrhythmic agent in patients with recurrent AF and less severe heart failure (NYHA class I–II) is not appropriate unless there is no suitable alternative.

There was a signal in the PALLAS trial that dronedarone was associated with increased sudden mortality in patients on concomitant digoxin therapy; hence the combined use of these two drugs is discouraged. No proarrhythmia has been documented with the use of dronedarone in any trial and there are few or any reports of torsades de pointes or ventricular tachycardia in the post-approval adverse event reporting. Therefore, it seems unnecessary to remove this option for the treatment of hypertension with left ventricular hypertrophy, where the risk from antiarrhythmic drugs is thought to be related to torsades de pointes.

Figure 4 Choice of antiarrhythmic drug according to underlying pathology.

Recommendations for oral antiarrhythmic agents

<table>
<thead>
<tr>
<th>Recommendations</th>
<th>Class</th>
<th>Level</th>
<th>Refs</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dronedarone is recommended in patients with recurrent AF as a moderately effective antiarrhythmic agent for the maintenance of sinus rhythm.</td>
<td>I</td>
<td>A</td>
<td>142, 144, 153</td>
</tr>
<tr>
<td>Short-term (4 weeks) antiarrhythmic therapy after cardioversion may be considered in selected patients e.g. those at risk for therapy-associated complications.</td>
<td>IIb</td>
<td>B</td>
<td>145</td>
</tr>
<tr>
<td>Dronedarone is not recommended in patients with permanent AF.</td>
<td>III</td>
<td>B</td>
<td>5</td>
</tr>
</tbody>
</table>

AF = atrial fibrillation.

Class of recommendation.

Level of evidence.

References.
Dronedarone has been associated with severe hepatotoxicity in a few instances. Hence, monitoring of liver function tests is advisable in patients on long-term dronedarone treatment. Since dronedarone is a P-glycoprotein inhibitor, it increases plasma concentrations of dabigatran; therefore concomitant use of the two drugs has to be avoided.

The current choice of antiarrhythmic drugs related to underlying pathophysiology is illustrated in Figure 4.

**Key points**

- Rhythm-control therapy, whether by antiarrhythmic drugs or by catheter ablation, is indicated to relieve symptoms associated with AF.
- Antiarrhythmic drugs should not be used for rate control in patients with permanent AF, unless appropriate rate control agents fail.
- In selected patients, limiting antiarrhythmic drug therapy to four weeks after cardioversion may help to improve safety.
- In a given patient, the choice of an antiarrhythmic drug should be driven by the perceived safety of the drug. This is more important than perceived efficacy.
- Dronedarone is appropriate for maintaining sinus rhythm in patients with paroxysmal or persistent AF.
- Dronedarone should not be given to patients with moderate or severe heart failure, and should be avoided in patients with less-severe heart failure, if appropriate alternatives exist.

### 8. Catheter ablation of atrial fibrillation

#### 8.1 New evidence for catheter ablation

Since the publication of the ESC AF Guidelines in 2010, several new sets of data have become available. The randomized MANTRA-PAF (Medical ANtiarrhythmic Treatment or Radiofrequency Ablation in Paroxysmal Atrial Fibrillation) trial compared catheter ablation of AF to antiarrhythmic drug therapy as a first-line rhythm control intervention in 294 patients. At 24-month follow-up, significantly more patients in the ablation group were free from any AF and symptomatic AF. Quality of life was significantly better in the ablation group at 12 and 24 months. However, total AF burden was not significantly different between both groups. Similar information has emerged from the results of the RAAFT II (Radiofrequency Ablation for Atrial Fibrillation Trial).

These data further support the 2010 recommendation that it is reasonable to recommend catheter ablation as first-line therapy for AF rhythm control in selected patients, i.e. those with paroxysmal AF preferring interventional treatment with a low risk profile for procedure-associated complications. Other reports also substantiate—albeit usually in single-centre, non-randomized data sets—that catheter ablation is more effective than antiarrhythmic drug therapy for the maintenance of sinus rhythm in patients with AF, mostly in patients without marked structural heart disease, with a low CHA2DS2-VASc score and with paroxysmal AF. All of these data support the statement in the guidelines that catheter ablation of AF is more effective than antiarrhythmic drug therapy in maintaining sinus rhythm.

The FAST (atrial Fibrillation catheter Ablation vs. Surgical ablation Treatment) trial compared the outcome of catheter ablation and surgical ablation in a relatively small patient population in a randomized study design. Rhythm outcome was better after surgical ablation. However, the complication rate after surgical ablation was significantly higher compared with catheter ablation. Another recent trial highlighted that technical difficulties, especially with respect to transmural lines, apply to surgical approaches to AF ablation.

While catheter ablation is more effective than antiarrhythmic drug therapy in maintaining sinus rhythm, the number of AF

---

**Figure 5** Antiarrhythmic drugs and/or left atrial ablation for rhythm control in AF.

---

AF = atrial fibrillation; HF = heart failure. *Usually pulmonary vein isolation is appropriate. **More extensive left atrial ablation may be needed. *Caution with coronary heart disease. *Not recommended with left ventricular hypertrophy. Heart failure due to AF = tachycardiomyopathy.
recurrences during the long-term follow-up seems to be significant. Several recent reports demonstrate that late recurrences of AF are common, even when suitable patients with ‘lone’ or ‘almost lone’ AF undergo catheter ablation in experienced centres. The most important predictor for such late recurrence appears to be early recurrence of AF after the ablation procedure, indicating that persistence of early recurrence is much more frequent than true late recurrence. Nonetheless a low rate of recurrences, which may be due to progression of atrial damage, continues to add up to relevant, long-term recurrence rates. Virtually all studies of catheter ablation of AF rely on isolation of the pulmonary vein as the target of the procedure. Whether full isolation of the pulmonary veins is needed to achieve the therapeutic effect is currently being studied.

While effective, catheter ablation of AF conveys a relevant risk of major complications. This is illustrated by the recent publication of the pilot survey of AF ablation within the EURObservational Research Programme. In this survey, which reported the outcome of more than 1000 ablation procedures carried out in high-volume centres throughout Europe, acute severe complication rates were 0.6% for stroke, 1.3% for tamponade, 1.3% for peripheral vascular complications, and around 2% for pericarditis. Similar complication rates have been reported from a large US ablation centre and, already available at the release of the 2010 ESC Guidelines, in the Worldwide AF Survey. As all of this information comes from voluntary registries and has an inherent tendency to bias for experienced centres; true complication rates may be higher. In a very recent medical database analysis in 4156 patients who underwent their initial ablation between 2005 and 2008, the complication rate was 5% and the rate of all-cause hospitalization in the first year after catheter ablation was 38.5%. Furthermore, several reports suggest that silent cerebral infarction, detectable by cerebral magnetic resonance imaging, may be induced by catheter ablation procedures.

According to several studies, the incidence of silent cerebral infarction varies significantly among different ablation technologies, ranging from approximately 4% to 35%. The reasons for these differences are not fully understood, but seem to be augmented by the use of specific ablation technologies. Although the clinical significance of silent cerebral infarction is unclear, these risks need to be carefully considered when selecting an ablation tool or technology. There is a clear and unmet need to develop safer technologies for AF ablation. Single-centre data series suggest that male patients with a low risk for stroke (CHA₂DS₂-VASc score of 0 or 1) are less likely to suffer from such complications than are older patients, women, and patients at increased risk for stroke.

It will take some years before large outcome trials of ablation-based rhythm control therapy will have reported the primary results. Until then, risk associated with AF ablation needs to be carefully weighed against the individual symptomatic benefit.

8.2 Catheter ablation in patients with heart failure
AF with concomitant HF-REF remains a challenging combination when rhythm control therapy is needed. The revised recommendations for antiarrhythmic drug therapy leave amiodarone as the only available antiarrhythmic agent in this setting (Figure 4). Many patients are rendered asymptomatic or mildly symptomatic (EHRA I or II) by such therapy, especially when heart failure and heart rate are well controlled. In patients who suffer from symptomatic AF recurrences on amiodarone therapy, catheter ablation remains as the sole choice for escalated rhythm control therapy. The main principles of rhythm control therapy apply to this group of patients as well, specifically that rhythm control therapy is indicated to improve AF-related symptoms (EHRA score II–IV), and that OAC therapy should be maintained, as the arrhythmia is likely to recur. It should be emphasized that the likelihood of maintaining sinus rhythm after catheter ablation is lower and the procedure-related risks may be higher in heart failure patients. In addition, correct assessment of AF-related symptoms may be more difficult with overlapping heart failure symptoms, emphasizing the need for an individual and informed decision for catheter ablation in patients with heart failure. In selected patients suffering from heart failure and treated in highly experienced centres, catheter ablation of AF may confer an improvement in left ventricular function. These recommendations are summarized in Figure 5.

8.3 Anticoagulant therapy peri-ablation
There is consensus that OAC is helpful to prevent thromboembolic complications around ablation procedures. This applies both to patients who have an indication for long-term OAC therapy and to patients without stroke risk factors, highlighting the fact that ablation somehow increases stroke risk around the time of the procedure.

Since the 2010 Guidelines on AF, there have been several reports to suggest that catheter ablation of AF may be performed with fewer complications when OAC therapy is continued (usually VKA, with INR 2.0–3.0), including one report on the outcome of ablation-induced cardiac tamponade in patients with and without continuous anticoagulation during the procedure. These reports conclude that continuous OAC is safe during ablation procedures, in line with previous recommendations for coronary revascularization procedures. Continuation of OAC therapy is also recommended in the recent HRS/EHRA/APHRS consensus statement on AF ablation, as an alternative to a bridging approach with heparin, for patients on OAC with VKA prior to catheter ablation. Experience with NOACs is limited. Initial reports, albeit using non-standardized protocols for the use of NOACs peri-ablation, suggest that the stroke risk may be slightly increased, which is counter-intuitive in light of the effects of NOAC in prevention of stroke in the general AF setting. While the exact relative risk of uninterrupted OAC with NOACs peri-ablation is not known, there is a known risk for bleeding events when switching or bridging of anticoagulants is applied. For patients taken off OAC before the ablation procedure, initiation of anticoagulation with NOAC shortly after the ablation procedure seems to be reasonable. This approach would also avoid any bridging with heparin.

At present, for patients on OAC with VKA, we therefore recommend undertaking catheter ablation of AF on continuous anticoagulation. Anticoagulant therapy should be kept at low therapeutic levels (such as an INR of 2 to 2.5) throughout ablation.
Such a regimen may help to reduce peri-procedural strokes, possibly including silent cerebral infarcts. As already recommended in the 2010 Guidelines, continuation of long-term OAC therapy post-ablation is recommended in all patients with a CHA2DS2-VASc score of ≥2, irrespective of apparent procedural success.

8.4 Safety first
There is much evolving technology that may help to reduce the risk of peri-procedural complications during AF ablation. As stated before, improving safety of catheter ablation should be a primary goal in the further development of this therapy. However, pathophysiological considerations suggest that rhythm control therapy may be best performed early after the initial diagnosis, as this time period may provide a ‘window of opportunity’ for effective rhythm control therapy. This concept clearly requires testing in controlled trials.

8.5 New considerations for AF catheter ablation
In the 2010 ESC Guidelines, catheter ablation of symptomatic paroxysmal AF after failed antiarrhythmic drug therapy was graded as a class IIa LoE A indication. Considering the results of randomized studies on catheter ablation of AF vs. antiarrhythmic drug therapy and recent publications from randomized and non-randomized trials, it is reasonable to upgrade this recommendation to class I, provided that the ablation is carried out by skilled operators. This is in line with the 2011 focused update from the ACCF/AHA and HRS, and the 2012 expert consensus statement on catheter and surgical ablation, co-authored by the EHRA. For patients with highly symptomatic paroxysmal AF with a low-risk profile for catheter ablation, primary catheter ablation should be considered.

These recommendations are restricted to: (i) highly experienced centres/investigators; (ii) appropriate patient selection; (iii) careful evaluation of treatment alternatives and (iv) patient preference. For patients with drug-refractory persistent and long-standing persistent AF, there is no change in recommendations. Currently there is no evidence to recommend catheter ablation of AF in asymptomatic patients.

Key points
- Catheter ablation is recommended as an alternative to antiarrhythmic drug therapy for patients with symptomatic recurrent paroxysmal AF on antiarrhythmic drug therapy, provided the procedure is performed by an experienced operator.
- Continuation of oral VKA therapy can be considered throughout the ablation procedure but robust data for NOACs are lacking.
- In selected patients with paroxysmal AF and no structural heart disease left atrial ablation is reasonable as first-line therapy.

9. Concluding remarks
This document is an update to the 2010 ESC Guidelines on the management of AF. It is not intended as a comprehensive new guideline and there are many other areas where small revisions to the 2010 Guidelines might be useful. These must await a further update or new guideline. Where relevant, flow charts and tables have been upgraded. This focused update will stand alone as a publication and will not be fully incorporated into a single publication together with the original Guidelines. A Pocket Guideline will be issued with all the recommendations, flow charts, and tables fully integrated.
References


47. ESC Guidelines 2012;12:344.e3522.


